대사 및 심혈관계 질환에 대한 아디포넥틴 수용체 활성제, 아디포론의 잠재적 역할 = Potential Role of Adiponectin Receptor Agonist, AdipoRon in Cardiometabolic Disease

다국어 초록 (Multilingual Abstract)

PURPOSE: Adiponectin has beneficial effects on metabolic and cardiovascular disease. Adiponectin receptor agonist, AdipoRon was discovered in 2013 and it may play an important role in preventing and ameliorating cardiometabolic disease. However, the physiological function and signal transduction of AdipoRon are still under way, and the potential role of AdipoRon in metabolic and cardiovascular diseases has not been clearly elucidated. The purpose of this review is to provide basic knowledge for the potential role of AdipoRon in cardiometabolic disease.
METHODS: In this review, we summarized the previous studies (published between 2013 and 2019) investigating the effect of Adipo- Ron on metabolic and cardiovascular disease.
RESULTS: The previous evidences have shown that AdipoRon treatment exerted its pleiotropic actions on metabolism related tissue and organs including adipose tissue, skeletal and cardiac muscles, liver, kidney, and vascular beds. Activation of adiponectin receptors may be effective for the treatment of metabolic and cardiovascular diseases due in part to activation of AMPK and PPARα signaling pathway as adiponectin does.
CONCLUSIONS: In conclusion, AdipoRon can be a novel therapeutic agent for the cardiometabolic disease. However, all of previous studies were conducted using experimental animal models and it is needed to investigate the role of AdipoRon in metabolic and cardiovascular disease in human.

참고문헌 (Reference)

1 Fontana L, "Visceral fat adipokine secretion is associated with systemic inflammation in obese humans" 56 (56): 1010-1013, 2007

2 Munasinghe PE, "Type-2diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway" 202 : 13-20, 2016

3 Picchi A, "Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome" 99 (99): 69-77, 2006

4 Yamauchi T, "The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity" 7 (7): 941-946, 2001

5 Booth FW, "The erosion of physical activity in Western societies : an economic death march" 58 (58): 1730-1734, 2015

6 Huang H, "The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice" 189 (189): 643-653, 2006

7 Kim Y, "The adiponectin receptor agonist AdipoRon ameliorates diabetic nephropathy in a model of type 2 diabetes" 29 (29): 1108-1127, 2018

8 Berg AH, "The adipocytesecreted protein Acrp30 enhances hepatic insulin action" 7 (7): 947-953, 2001

9 Viollet B, "Targeting the AMPK pathway for the treatment of type 2 diabetes" 14 : 3380-3400, 2009

10 Kusminski CM, "Targeting adipose tissue in the treatment of obesity-associated diabetes" 15 (15): 639-660, 2016

11 Halberg N, "Systemic fate of the adipocyte-derived factor adiponectin" 58 (58): 1961-1970, 2009

12 Lefebvre P, "Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis" 116 (116): 571-580, 2006

13 Booth FW, "Role of inactivity in chronic diseases : evolutionary insight and pathophysiological mechanisms" 97 (97): 1351-1402, 2017

14 Wang Y, "Restoring diabetes-induced autophagic flux arrest in ischemic/reperfused heart by ADIPOR(adiponectin receptor)activation involves both AMPK-dependent and AMPK-independent signaling" 13 (13): 1855-1869, 2017

15 Fruebis J, "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice" 98 (98): 2005-2010, 2001

16 Goldstein BJ, "Protective vascular and myocardial effects of adiponectin" 6 (6): 27-35, 2009

17 Malih S, "Promigratory and proangiogenic effects of AdipoRon on bone marrowderived mesenchymal stem cells : an in vitro study" 39 (39): 39-44, 2017

18 Hotta K, "Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2diabetic patients" 20 (20): 1595-1599, 2000

19 Kubota N, "Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways" 281 (281): 8748-8755, 2006

20 Miki Okada-Iwabu, "Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity" 대한당뇨병학회 39 (39): 363-372, 2015

21 Iwaki M, "Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors" 52 (52): 1655-1663, 2003

22 Holland WL, "Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis" 6 (6): 267-275, 2017

23 Weyer C, "Hypoadiponectinemia in obesity and type 2 diabetes : close association with insulin resistance and hyperinsulinemia" 86 (86): 1930-1935, 2001

24 Wang Y, "Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice" 93 : 123-131, 2016

25 Farias JM, "Exercise training performed simultaneously to a high-fat diet reduces the degree of insulin resistance and improves adipoR1-2/APPL1 protein levels in mice" 11 : 134-, 2012

26 Marinho R, "Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss" 227 (227): 2917-2926, 2012

27 이세원, "Effects of interventions on adiponectin and adiponectin receptors" 한국운동재활학회 10 (10): 60-68, 2014

28 Choi KC, "Effect of PPAR-alpha and-gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats" 336 (336): 747-753, 2005

29 Christiansen T, "Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin" 95 (95): 911-919, 2010

30 Zhu P, "Design, synthesis chalcone derivatives as AdipoR agonist for type 2 diabetes" 92 (92): 1525-1536, 2018

31 Pajvani UB, "Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity" 279 (279): 12152-12162, 2004

32 Bluher M, "Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle : associations with metabolic parameters and insulin resistance and regulation by physical training" 91 (91): 2310-2316, 2006

33 Holland WL, "Cell Biology. Ronning after the adiponectin receptors" 342 (342): 1460-1461, 2013

34 Sciarretta S, "Boosting autophagy in the diabetic heart : a translational perspective" 5 (5): 394-402, 2015

35 Yamashita T, "An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis" 8 (8): 11843-, 2018

36 Wu X, "An adiponectin receptor agonist reduces type 2 diabetic periodontitis" 98 : 313-321, 2019

37 Stern JH, "Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk" 23 (23): 770-784, 2016

38 Okamoto Y, "Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice" 106 (106): 2767-2770, 2002

39 Hong K, "Adiponectin receptor agonist, AdipoRon, causes vasorelaxation predominantly via a direct smooth muscle action" 23 (23): 207-220, 2016

40 Wang SJ, "Adiponectin receptor agonist AdipoRon suppresses adipogenesis in C3H10T1/2 cells through the adenosine monophosphateactivated protein kinase signaling pathway" 16 (16): 7163-7169, 2017

41 Choi SR, "Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy" 85 : 348-360, 2018

42 Tsubakio-Yamamoto K, "Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages" 375 (375): 390-394, 2008

43 Guo R, "Adiponectin and its receptors are involved in hypertensive vascular injury" 17 (17): 209-215, 2018

44 Lee S, "Adiponectin abates diabetes-induced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice" 303 (303): H106-H115, 2012

45 Deng Y, "Adipokines as novel biomarkers and regulators of the metabolic syndrome" 1212 : E1-E19, 2010

46 Ouchi N, "Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages" 103 (103): 1057-1063, 2001

47 Zhang Y, "AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings" 309 (309): E275-E282, 2015

48 Zhang N, "AdipoRon, an adiponectin receptor agonist, attenuates cardiac remodeling induced by pressure overload" 96 (96): 1345-1357, 2018

49 Fairaq A, "AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK : Implications toward suppression of neointimal hyperplasia" 119 : 289-302, 2017

50 Hu X, "AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway" 51 : 20-30, 2019

51 Zhang BB, "AMPK : an emerging drug target for diabetes and the metabolic syndrome" 9 (9): 407-416, 2009

52 Okada-Iwabu M, "A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity" 503 (503): 493-499, 2013